Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial
详细信息 查看全文
- 作者：Naama Levy-Coopermana ; 1 ; nlevy-cooperman@altreos.com" class="auth_mail" title="E-mail the corresponding author ; Kerri A. Schoedela ; 1 ; kschoedel@altreos.com" class="auth_mail" title="E-mail the corresponding author ; Bijan Chakrabortya ; 2 ; bijan.chakraborty@rogers.com" class="auth_mail" title="E-mail the corresponding author ; David Blumb ; david.blum@sunovion.com" class="auth_mail" title="E-mail the corresponding author ; Hailong Chengb ; hailong.cheng@sunovion.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：λz ; elimination rate constant ; AED ; antiepileptic drug ; AE ; adverse event ; ANCOVA ; analysis of covariance ; ARCI ; Addiction Research Center Inventory ; ALP ; alprazolam ; AST ; aspartate aminotransferase ; AUC ; area under the curve ; AUC0&ndash ; last ; AUC from time zero to the last measurable concentration ; AUC0&ndash ; &infin ; ; AUC from time zero to infinity ; BMI ; body mass index ; CI ; confidence interval ; CL/F ; apparent total clearance ; Cmax ; maximum observed plasma concentration ; CNS ; central nerv
- 刊名：Epilepsy & Behavior
- 出版年：2016
- 出版时间：August 2016
- 年：2016
- 卷：61
- 期：Complete
- 页码：63-71
- 全文大小：901 K
文摘
- •
Phase I study of abuse potential in humans (recreational CNS depressant users).
- •
Evaluating abuse potential of eslicarbazepine acetate (ESL) versus alprazolam and placebo.
- •
The effects of ESL on subjective measures of abuse potential were less than those of alprazolam.
- •
Little evidence of abuse potential was apparent with single doses of ESL in recreational CNS users.
- •
At higher/supratherapeutic doses, drug–liking was slightly increased versus placebo.